The 13th JFCR−ISCC

December 3-4, 2008
Keidanren Hall

We would like to ask your participation in the 13th Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy, which will be held on December 3 (Wed) and 4 (Thu), 2008, in Keidanren Hall, Otemachi, Tokyo, Japan.
Recently many international co-operative studies are ongoing for the development of new antitumor agents. We believe that such world-wide, harmonized study should become much more important in the future. Under this circumstance, we are organizing a series of international symposium entitled "International Symposium on Cancer Chemotherapy". The purpose of the symposium is to discuss recent progress in the development of new antitumor agents and future perspectives in cancer chemotherapy. The Symposia were successfully held in Tokyo in 1996-2007 with about 300-350 participants. It is hoped that the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate workers in Japan.
We are looking forward to seeing you in the Symposium.

December 3, 2008 (Wednesday)

12:00-12:45

(Committee Members' Meeting)

13:00-13:10

Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)

Welcome and Introduction

I c-Met Inhibitors

Chairpersons:Mace Rothenberg (Vanderbilt-Ingram Cancer Center, Nashville)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

13:10-13:40

Donald Bottaro (National Cancer Institute, Bethesda)

HGF/Met signaling in cancer

13:40-14:10

Ravi Salgia (University of Chicago Medical Center, Chicago)

Met inhibition in cancer - especially lung cancer

14:10-14:20

Discussion

14:20-14:40

Coffee Break

Special Lecture I

Chairperson:Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)

14:40-15:20

Bruce A Chabner (MGH Cancer Center, Boston)

Title TBA

II Kinase Inhibitors

Chairpersons:Mark J Ratain (University of Chicago, Chicago)
Yoshikazu Sugimoto (Keio University, Tokyo)

15:20-15:45

Maria Koehler (GlaxoSmithKline, Philadelphia)

Predicting for maximum benefit - the tale of lapatinib

15:45-16:10

Jay Feingold (Wyeth Research, Cambridge)

Temsirolimus: New targeted therapy for renal cell carcinoma

16:10-16:35

Eisei Shin (AstraZeneca, Osaka)

VEGFR inhibitor: AZD2171

16:35-16:55

Hideo Kunitoh (National Cancer Center Hospital, Tokyo)

Randomized comparisons of gefitinib and cytotoxic chemotherapy in NSCLC patients

16:55-17:05

Discussion

IIILenalidomide and Hematologic Malignancies

Chairpersons:Ravi Salgia (University of Chicago Medical Center, Chicago)
Tomoki Naoe (Nagoya University, Nagoya)

17:05-17:25

Kaoru Tohyama (Kawasaki Medical University, Kurashiki)

Lenalidomide and myelodysplastic syndrome

17:25-17:45

Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

Recent trends in treatment for hematologic malignancies

17:45-17:50

Discussion

18:00-19:00

Mixer

December 4, 2008 (Thursday)

IV New Targets and New Drugs (Part 1)

Chairpersons:Donald Bottaro (National Cancer Institute, Bethesda)
Yoshiro Niitsu (Sapporo Medical University, Sapporo)

9:30-10:00

Mace Rothenberg (Vanderbilt-Ingram Cancer Center, Nashville)

New targets in the treatment of pancreatic and colorectal cancer

10:00-10:20

Mikihiko Naito (University of Tokyo, Tokyo)

Activating auto-ubiquitylation, a novel strategy to antagonize cIAP1 overexpressed in cancer

10:20-10:40

Isamu Okamoto (Kinki University School of Medicine, Osaka)

YM155, a novel small molecule survivin suppressant

10:40-10:50

Discussion

10:50-11:05

Coffee Break

V New Targets and New Drugs (Part 2)

Chairpersons:Stefan Sleijfer (Erasmus Univ. Medical Center, Rotterdam)
Michihiko Kuwano (Kyushu University, Fukuoka)

11:05-11:35

Alan Ashworth (Institute of Cancer Research, London)

PARP inihbitor and synthetic lethal approaches to cancer treatment

11:35-12:00

Axel-Rainer Hanauske (Eli Lilly, Indianapolis)

Lilly's Oncology Pipeline: small molecules, antibodies, antisense

12:00-12:10

Discussion

12:25-13:20

Luncheon Seminars

Seminar I Sponsored by GlaxoSmithKline and EFPIA

Chairperson: Kazuto Nishio (Kinki University, Osaka)

Maria Koehler (GlaxoSmithKline, Philadelphia)

Tyrosine kinase inhibitors - some challenges before they reach the right patients with cancer

Seminar II Sponsored by Eli Lilly and PhRMA

Chairperson: Toshihiko Kobayashi (PhRMA, Tokyo)

Joe Shih and Axel-Rainer Hanauske (Eli Lilly, Indianapolis)

Alimta: its discovery and clinical development

Special Lecture II

Chairperson:Saburo Sone (Tokushima University, Tokushima)

13:35-14:15

Isaiah J Fidler (Unversity of Texas MD Anderson Cancer Center, Houston)

Biology of brain metastasis and resistance to chemotherapy

VI Transcriptional Control

Chairpersons:Alan Ashworth (Institute of Cancer Research, London)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)

14:15-14:35

Norio Komatsu (University of Yamanashi School of Medicine, Yamanashi)

HIF-1: a potential therapeutic target in hematologic malignancies

14:35-14:55

Minoru Yoshida (RIKEN, Wako)

Splicing factor SF3b as a novel target for cancer therapy

14:55-15:25

Yves G Pommier (National Cancer Institute, Bethesda)

Molecular pharmacology of Trabectedin (Yondelis?; ecteinascidin 743): a specific inhibitor of transcription

15:25-15:35

Discussion

15:35-15:50

Coffee Break

VIISignal Transduction and Combination Therapies

Chairpersons:Yves G Pommier (National Cancer Institute, Bethesda)
Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)

15:50-16:20

Stefan Sleijfer (Erasmus Univ. Medical Center, Rotterdam)

Combination of cancer cell specific therapies and conventional chemotherapy

16:20-16:45

Elwyn Loh (Amgen, San Francisco)

Targeting IGF-1R for cancer therapy - AMG479

16:45-17:05

Yasuhiko Nishioka (Tokushima University, Tokushima)

E7080, multiple kinases inhibitor for malignant pleural mesothelioma

17:05-17:35

Mark J Ratain (University of Chicago, Chicago)

Blockbuster plus wonder drug: challenges in developing new drug combinations

17:35-17:45

Discussion

17:45-17:55

Bruce A Chabner (MGH Cancer Center, Boston)

Closing Remark

Access Map

Keidanren Kaikan
1-9-4, Otemachi, Chiyoda-ku, Tokyo 100-8188
TEL: +81-3-5204-1500
FAX: +81-3-5255-6255
http://www.keidanren.or.jp/english/profile/map.html

For further information

please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-10-6, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482

Page TOP